Yingli Pharma announced that it reached strategic collaboration with Hengrui Medicine, a partnership which will significantly accelerate the expansion of Yingli Pharma's oncology business in China. As an innovation-driven enterprise, Yingli Pharma demonstrates commitment to continuous investment in R&D and is committed to the research, development and commercialization of new drugs for hematological tumors, solid tumors and kidney-related metabolic diseases. The collaboration with Hengrui Medicine is a significant milestone that will enable Yingli Pharma to further promote the commercialization of developed innovative drugs.